Imdelltra (tarlatamab-dlle)

P1, N=100, Recruiting, Amgen | Trial completion date: Feb 2028 --> Mar 2030

P1, N=269, Active, not recruiting, Amgen | Trial completion date: Apr 2026 --> Oct 2026 | Trial primary completion date: Apr 2025 --> Oct 2025

P2, N=32, Not yet recruiting, National Taiwan University Hospital

P1/2, N=30, Not yet recruiting, University of Arizona

Given that tarlatamab is the first T-cell engager approved for the treatment of small cell lung cancer, raising awareness with regard to the monitoring and management of tarlatamab-associated adverse events is essential. Here, the authors describe the timing, occurrence, and duration of these adverse events and review the management and risk-mitigation strategies used by clinical investigators during the DeLLphi-301 trial.

P2, N=29, Not yet recruiting, Jonsson Comprehensive Cancer Center

P2, N=32, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

P2, N=44, Not yet recruiting, University Health Network, Toronto

P1, N=100, Recruiting, Amgen | Trial completion date: May 2028 --> Feb 2028 | Trial primary completion date: May 2027 --> Feb 2027

P2, N=240, Not yet recruiting, Amgen

Her tumor strongly expressed DLL3 protein and had clinical response to tarlatamab therapy. This case indicates that this novel therapy may be an efficacious option in other pulmonary neuroendocrine cancers.

In patients with previously treated SCLC, tarlatamab demonstrated dose-proportional pharmacokinetic and extended half-life characteristics that support a Q2W dosing interval. Neither Japanese race nor ADA had a clinically relevant impact on exposures.

P1, N=269, Active, not recruiting, Amgen | Trial completion date: Oct 2025 --> Apr 2026 | Trial primary completion date: Oct 2024 --> Apr 2025

Despite the improved outcomes associated with immunotherapy in SCLC, the overall clinical benefit remains modest. Further preclinical and clinical studies are essential to identify optimal treatment regimens and enhance therapeutic efficacy.

The study found that tarlatamab given every 2 weeks shrank SCLC in participants with SCLC who received previous treatments. Participants given the 10 mg tarlatamab dose had fewer side effects than those given the 100 mg tarlatamab dose.Clinical Trial Registration: NCT05740566 (DeLLphi-304) (ClinicalTrials.gov).

P1, N=41, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Jul 2024 | Trial primary completion date: Aug 2025 --> Jul 2024

P1, N=23, Completed, Amgen | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024

P1, N=100, Recruiting, Amgen | Not yet recruiting --> Recruiting

P1, N=23, Active, not recruiting, Amgen | Phase classification: P1b --> P1

Before the approval of Tarlatamab-dlle, only a few drugs, such as Atezolizumab and Durvalumab, received FDA approval for treating extensive-stage SCLC. It might be possible that Tarlatamab-dlle received accelerated FDA approval for extensive-stage SCLC, leaving some questions unanswered at this stage. This manuscript is focused on clinical, pre-clinical, and other pharmacological aspects of Tarlatamab-dlle for extensive-stage SCLC.

P2, N=30, Recruiting, Amgen | Not yet recruiting --> Recruiting

P1, N=184, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=340 --> 184 | Trial completion date: Jun 2029 --> Aug 2028 | Trial primary completion date: Jun 2029 --> Aug 2028

P1, N=100, Not yet recruiting, Amgen

P2, N=222, Active, not recruiting, Amgen | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025

P3, N=509, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

P1, N=340, Recruiting, Amgen | Trial completion date: Jan 2027 --> Jun 2029 | Trial primary completion date: Jan 2027 --> Jun 2029

P1, N=269, Active, not recruiting, Amgen | N=392 --> 269

Tarlatamab is under regulatory review in Brazil, Canada, Israel and the UK, and clinical studies are underway in multiple countries. This article summarizes the milestones in the development of tarlatamab leading to this first approval for ES-SCLC with disease progression on or after platinum-based chemotherapy.

P2, N=30, Not yet recruiting, Amgen

P1, N=392, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

Specific tumor biomarkers, such as delta-like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious, novel immunomodulating targeted treatments like bispecific T-cell engaging monoclonal antibodies (tarlatamab) and chemotherapy with PARP inhibitors...CTCs have been studied for their prognostic ability in SCLC; however, their value in guiding treatment decisions is yet to be elucidated. This review explores novel and promising targeted therapies in SCLC, summarizes current knowledge of CTCs in SCLC, and discusses how CTCs can be utilized for precision medicine.

Moreover, SCLC can also develop intratumoral heterogeneity linked mainly to the concept of cellular plasticity, mostly due to the development of resistance to therapies. The aim of this review is to quickly present the current standard of care of ES-SCLC, to focus on the molecular landscapes and subtypes of SCLC, subsequently present the most promising therapeutic strategies under investigation, and finally recap the future directions of ongoing clinical trials for this aggressive disease which still remains a challenge.

"Tarlatamab, targeting DLL3 and CD3, showed a 40% response rate in previously treated patients... In 248 early-stage SCLC, positivity for DLL3 was 58% with IHC and 87% with mRNA ISH. A trend for improved survival in patients with no DLL3 expression was observed. Future studies on DLL3 might improve SCLC treatment SCLC."

P3, N=550, Recruiting, Amgen | Not yet recruiting --> Recruiting

Although rovalpituzumab tesirine (Rova-T) showed promise in a phase II study, it failed to produce favorable results in subsequent phase III trials, leading to the cessation of its development...Tarlatamab, for instance, demonstrated enhanced response rates and progression-free survival compared to the standard of care in a phase II trial; its biologics license application (BLA) is currently under US Food and Drug Administration (FDA) review...DLL3-targeted therapies hold substantial potential for SCLC management. Future clinical trials will be crucial for comparing treatment outcomes among various approaches and exploring combination therapies to improve patient survival outcomes.

P1, N=340, Recruiting, Amgen | Trial primary completion date: Dec 2025 --> Jan 2027

Findings from this phase 1 study of tarlatamab in pts with NEPC demonstrated manageable safety with encouraging anti-tumor activity in DLL3 expressing NEPC. Further investigation is ongoing.

P1, N=41, Active, not recruiting, Amgen | Phase classification: P1b --> P1 | Trial primary completion date: Mar 2023 --> Aug 2025

P3, N=400, Recruiting, Amgen | Not yet recruiting --> Recruiting

P2, N=222, Active, not recruiting, Amgen | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Oct 2024

P3, N=490, Recruiting, Amgen | N=700 --> 490 | Trial primary completion date: Sep 2025 --> Aug 2027

P3, N=400, Not yet recruiting, Amgen | Trial primary completion date: Jul 2028 --> Oct 2029